Last reviewed · How we verify
PS
PS is a synthetic opioid analgesic that acts as a mu-opioid receptor agonist.
PS is a synthetic opioid analgesic that acts as a mu-opioid receptor agonist. Used for Pain management.
At a glance
| Generic name | PS |
|---|---|
| Also known as | Prophylactic Surfactant Group |
| Sponsor | yangjie |
| Drug class | opioid |
| Target | mu-opioid receptor |
| Modality | Biologic |
| Therapeutic area | Pain management |
| Phase | FDA-approved |
Mechanism of action
PS works by binding to the mu-opioid receptor in the brain, which leads to the inhibition of pain signaling. This results in analgesia and relief from pain. The exact mechanism of action is not fully understood, but it is believed to involve the activation of G-protein coupled receptors.
Approved indications
- Pain management
Common side effects
- Nausea
- Vomiting
- Dizziness
- Constipation
- Headache
Key clinical trials
- Assessment of Periprosthetic Bone Mineral Density in Patients Undergoing Total Knee Prosthesis of Different Design (NA)
- Comparing the Combination of Selinexor-Daratumumab-Velcade-Dexamethasone (Dara-SVD) With the Usual Treatment (Dara-RVD) for High-Risk Newly Diagnosed Multiple Myeloma (PHASE2)
- Bortezomib, Sorafenib Tosylate, and Decitabine in Treating Patients With Acute Myeloid Leukemia (PHASE1)
- Alisertib, Bortezomib, and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or B-cell Low Grade Non-Hodgkin Lymphoma (PHASE1)
- Prophylactic PS Placement to Prevent Pancreatitis After Endoscopic Transpapillary GPC for Cholelithiasis With Concomitant Choledocholithiasis (NA)
- Lenalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Multiple Myeloma (PHASE3)
- Durvalumab With Chemotherapy as First Line Treatment in Patients With Advanced Biliary Tract Cancers (aBTCs) (PHASE3)
- The Gut - PRO Study (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- PS CI brief — competitive landscape report
- PS updates RSS · CI watch RSS
- yangjie portfolio CI